Market Overview

Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program


Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the
"Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, announced today
acceptance into the National Institutes of Health ("NIH")
Commercialization Accelerator Program ("CAP") 2018-2019.

The Company was selected for CAP due to its successful completion of a
Small Business Innovation Research ("SBIR") Fast Track grant from the
NIH (grant number R44 AR067583-01A1; Frederick Cope, PI) entitled 99mTc-Tilmanocept
for Targeting Rheumatoid Arthritis ("RA")-Driving Macrophages.

Navidea has been assigned to the Advanced Commercialization Track
("ACT") of CAP.

CAP is designed to facilitate and accelerate the commercial success of
SBIR-funded commercialization projects. Navidea will participate in CAP
for nine months beginning in October 2018, during which the program will
provide technical support for Navidea's RA imaging-related
commercialization initiative and is expected to facilitate establishment
of contacts between Navidea and potential corporate collaborators and
partners and between Navidea and potential investors.

"Navidea is pleased and honored to have been selected for the highly
competitive CAP program," said Mr. Jed A. Latkin, Chief Executive
Officer of Navidea. "Selection in this program reflects the strength of
our team and an opportunity for our novel pipeline of diagnostics. I
expect that participation in the program will provide the Company with
non-dilutive assistance to advance our RA program and will increase
Navidea's exposure to industry players and potential investors. We look
forward to working with the CAP network to develop a comprehensive
marketing strategy, which has the potential to propel Navidea towards
commercial success."

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization

For more information, please visit

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Such forward-looking statements include those relating
to the Company's participation in CAP, its growth and exposure to
industry participants, its marketing strategy, its potential for
commercial success, and ability to establish contacts with potential
collaborators, partners, and investors.
We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends affecting the
financial condition of our business. These forward-looking statements
are subject to a number of risks, uncertainties and assumptions,
including, among other things: general economic and business conditions,
both nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas; our ability to successfully complete research and
further development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug candidates;
our ability to successfully commercialize our drug candidates; our
expectations and estimates concerning future financial performance,
financing plans and the impact of competition; our ability to raise
capital sufficient to fund our development and commercialization
programs; our ability to implement our growth strategy; anticipated
trends in our business; advances in technologies; and other risk factors
and detailed in our most recent Annual Report on Form 10-K and other SEC
filings. You are urged to carefully review and consider the disclosures
found in our SEC filings, which are available at or

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at